Pivotal ENLIGHTEN Phase 3 clinical program and BEACON Phase 2 clinical trial targeting a broad spectrum of chronic rhinosinusitis  (CRS) patients, continued enrollment Industry leader Richard Nieman , MD, appointed Chief Medical Officer In April 2022 , secured $96.3 million in net proceeds in an

WATERTOWN, Mass. , July 5, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc . (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased

Industry leader with substantial U.S. and global experience in drug development and medical affairs joins Lyra as the Company's late-stage product candidates advance in the clinic WATERTOWN, Mass. , July 5, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc .

WATERTOWN, Mass. , June 17, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (NASDAQ: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo ™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased

WATERTOWN, Mass. , May 26, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased

In April 2022 , secured $100.5 million in gross proceeds in an at-the-market, private placement of common stock that is expected to support two pivotal data readouts; cash runway extended until mid-2024 Pivotal ENLIGHTEN Phase 3 clinical program and BEACON Phase 2 clinical trial targeting a broad

WATERTOWN, Mass. , May 5, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased

LYR-210 provided up to 24 weeks of clinically meaningful global symptom improvement in CRS patients LYR-210 achieved significant improvement in each CRS symptom subdomain of the SNOT-22 compared to control LYR-210 may improve mental and physical health and quality of life of CRS patients WATERTOWN,

WATERTOWN, Mass. , April 25, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (NASDAQ: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose, and throat (ENT) passages and other diseased

LYR-210 Data on Impact of Long-Acting Implantable Corticosteroid Matrices in Patients with CRS Selected as a Top Clinical Abstract Both Presentations Demonstrate Potential Benefit of LYR-210 to Chronic Rhinosinusitis Patients WATERTOWN, Mass. , April 21, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc.